Senti Biosciences EBIT

Senti Biosciences (SNTI) currently reports a EBIT of $-55M as of March 2026. That compares with $-46M in the prior-year period — down 21.3% year over year. That is above the sector sector average of $-69M. Use the charts on this page to explore Senti Biosciences's EBIT history and peer comparisons.

Senti Biosciences's EBIT decreased from $-46M to $-55M — a 21.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Senti Biosciences's EBIT of $-55M is higher than the its sector sector average of $-69M. That is roughly 19.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Senti Biosciences reported $-55M in EBIT as of March 2026. That compares with $-46M in the prior-year period — down 21.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-55M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-69M. From there, open related valuation or income-statement pages for Senti Biosciences, and consider following SNTI for alerts when major investors trade the stock.